SUSMED (4263) Fundamentals 2026 — Revenue Analysis | SniperIQ
SUSMED (4263) is a JP-listed Healthcare company in Biotechnology with a market capitalization of ¥12.1B, trading at ¥719.00 on the JPX. This SniperIQ fundamentals page covers SUSMED's valuation, profitability (net margin -176.2%), revenue (¥463M in FY2024), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is SUSMED's market cap?
SUSMED (4263) has a market capitalization of approximately ¥12.1B, trading at ¥719.00 on the JPX. Market cap moves with the live share price.
What is SUSMED's P/E ratio?
SUSMED's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 3.0x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is SUSMED?
SUSMED runs a net profit margin of -176.2%, a gross margin of 94.5%, and an operating margin of -180.6%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does SUSMED generate?
SUSMED reported revenue of ¥463M for fiscal year 2024, with net income of -¥298M and earnings per share (EPS) of -17.77. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does SUSMED pay a dividend?
SUSMED does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is SUSMED financially healthy?
SUSMED carries a debt-to-equity ratio of 0.00x and a current ratio of 35.29x, with a market beta of 1.21. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is SUSMED a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For SUSMED (4263) the key facts are: market cap ¥12.1B, revenue ¥463M, 52-week range 587-1231. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track SUSMED's full fundamentals live
Get SUSMED's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.